Elena Garralda

Elena Garralda

Auto-generated profile, based on publicly available information

Elena Garralda

Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
BSBruno Sangro
Bruno Sangro
CGCarlos Gomez-Martin
Carlos Gomez-Martin
MMManuel de la Mata
Manuel de la Mata
MIMercedes Iñarrairaegui
Mercedes Iñarrairaegui
EGElena Garralda
Elena Garralda
JPJesús Prieto
Jesús Prieto

1 July 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
VSVivek Subbiah
Vivek Subbiah
JGJustin F. Gainor
Justin F. Gainor
RRRami Rahal
Rami Rahal
JBJason D. Brubaker
Jason D. Brubaker
JKJoseph L. Kim
Joseph L. Kim
EEErica K. Evans
Erica K. Evans
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapies have been designed to target RET; treatment has been limited to multikinase inhibitors (MKI), which can have significant off-target toxicities and limited efficacy. BLU-667 is a highly potent and selective RET inhibitor designed to overcome these limitations. In vitro, BLU-667 demonstrated ≥10-fold increased potency over approved MKIs against oncogenic RET variants and resistance mutants. In vivo, BLU-667 potently inhibited growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2. In first-in-human testing, BLU-667 significantly inhibited RET signaling and induced durable clinical responses in patients with RET-altered NSCLC and MTC without notable off-target toxicity, providing clinical validation for selective RET targeting. Significance: Patients with RET-driven cancers derive limited benefit from available MKIs. BLU-667 is a potent and selective RET inhibitor that induces tumor regression in cancer models with RET mutations and fusions. BLU-667 attenuated RET signaling and produced durable clinical responses in patients with RET-altered tumors, clinically validating selective RET targeting. Cancer Discov; 8(7); 836–49. ©2018 AACR. See related commentary by Iams and Lovly, p. 797. This article is highlighted in the In This Issue feature, p. 781

27 October 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
IMInes Marin
Ines Marin
OBOlga Boix
Olga Boix
AGAndrea Garcia-Garijo
Andrea Garcia-Garijo
ISIsabelle Sirois
Isabelle Sirois
ACAdrià Caballe
Adrià Caballe
MSManuel Serrano
Manuel Serrano
Cellular senescence is a stress response that activates innate immune cells, but little is known about its interplay with the adaptive immune system. Here, we show that senescent cells combine several features that render them highly efficient in activating dendritic cells (DC) and antigen-specific CD8 T cells. This includes the release of alarmins, activation of IFN signaling, enhanced MHC class I machinery, and presentation of senescence-associated self-peptides that can activate CD8 T cells. In the context of cancer, immunization with senescent cancer cells elicits strong antitumor protection mediated by DCs and CD8 T cells. Interestingly, this protection is superior to immunization with cancer cells undergoing immunogenic cell death. Finally, the induction of senescence in human primary cancer cells also augments their ability to activate autologous antigen-specific tumor-infiltrating CD8 lymphocytes. Our study indicates that senescent cancer cells can be exploited to develop efficient and protective CD8-dependent antitumor immune responses. Significance: Our study shows that senescent cells are endowed with a high immunogenic potential—superior to the gold standard of immunogenic cell death. We harness these properties of senescent cells to trigger efficient and protective CD8-dependent antitumor immune responses. See related article by Chen et al., p. 432. This article is highlighted in the In This Issue feature, p. 247

11 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMónica Pascual-García
Mónica Pascual-García
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
EPEster Planas-Rigol
Ester Planas-Rigol
CRCarlota Rubio-Perez
Carlota Rubio-Perez
RIRaffaella Iurlaro
Raffaella Iurlaro
JSJoan Seoane
Joan Seoane
Cancer response to immunotherapy depends on the infiltration of CD8+ T cells and the presence of tumor-associated macrophages within tumors. Still, little is known about the determinants of these factors. We show that LIF assumes a crucial role in the regulation of CD8+ T cell tumor infiltration, while promoting the presence of protumoral tumor-associated macrophages. We observe that the blockade of LIF in tumors expressing high levels of LIF decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8+ T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival.

6 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EGElena Garralda
Elena Garralda
MBMarie-Eve Beaulieu
Marie-Eve Beaulieu
Victor MorenoVictor Moreno
Victor Moreno
SCSílvia Casacuberta-Serra
Sílvia Casacuberta-Serra
SMSandra Martínez-Martín
Sandra Martínez-Martín
ECEmiliano Calvo
Emiliano Calvo
Among the ‘most wanted’ targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein. Here we present results from a phase 1 study of OMO-103 in advanced solid tumors, established to examine safety and tolerability as primary outcomes and pharmacokinetics, recommended phase 2 dose and preliminary signs of activity as secondary ones. A classical 3 + 3 design was used for dose escalation of weekly intravenous, single-agent OMO-103 administration in 21-day cycles, encompassing six dose levels (DLs). A total of 22 patients were enrolled, with treatment maintained until disease progression. The most common adverse events were grade 1 infusion-related reactions, occurring in ten patients. One dose-limiting toxicity occurred at DL5. Pharmacokinetics showed nonlinearity, with tissue saturation signs at DL5 and a terminal half-life in serum of 40 h. Of the 19 patients evaluable for response, 12 reached the predefined 9-week time point for assessment of drug antitumor activity, eight of those showing stable disease by computed tomography. One patient defined as stable disease by response evaluation criteria in solid tumors showed a 49% reduction in total tumor volume at best response. Transcriptomic analysis supported target engagement in tumor biopsies. In addition, we identified soluble factors that are potential pharmacodynamic and predictive response markers. Based on all these data, the recommended phase 2 dose was determined as DL5 (6.48 mg kg−1).ClinicalTrials.gov identifier: NCT04808362.

10 December 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CGCarlos Gomez-Martin
Carlos Gomez-Martin
JPJose Carlos Plaza
Jose Carlos Plaza
Roberto Pazo-CidRoberto Pazo-Cid
Roberto Pazo-Cid
ASAntonia Salud
Antonia Salud
FPFrancesc Pons
Francesc Pons
FLFernando Lopez-Rios
Fernando Lopez-Rios
Purpose: Previous studies have highlighted the importance of an appropriate human epidermal growth factor receptor 2 (HER2) evaluation for the proper identification of patients eligible for treatment with anti-HER2 targeted therapies. Today, the relationship remains unclear between the level of HER2 amplification and the outcome of HER2-positive gastric cancer treated with first-line chemotherapy with trastuzumab. The aim of this study was to determine whether the level of HER2 gene amplification determined by the HER2/CEP17 ratio and HER2 gene copy number could significantly predict some benefit in overall survival and response to therapy in advanced gastric cancer treated with trastuzumab-based chemotherapy. Patients and Methods: Ninety patients with metastatic gastric cancer treated with first-line trastuzumab-based chemotherapy were studied. The optimal cutoff values for HER2/CEP17 ratio and HER2 gene copy number (GCN) for discriminating positive results in terms of response and prolonged survival were determined using receiver operating characteristic curves analyses. Results: In this study, a median HER2/CEP17 ratio of 6.11 (95% CI, 2.27 to 21.90) and a median HER2 gene copy number of 11.90 (95% CI, 3.30 to 43.80) were found. A mean HER2/CEP17 ratio of 4.7 was identified as the optimal cutoff value discriminating sensitive and refractory patients (P = .005). Similarly, the optimal cutoff for predicting survival longer than 12 months was 4.45 (P = .005), and for survival longer than 16 months was 5.15 (P = .004). For HER2 GCN, the optimal cutoff values were 9.4, 10.0, and 9.5, respectively (P = .02). Conclusion: The level of HER2 gene amplification significantly predicts sensitivity to therapy and overall survival in advanced gastric cancer treated with trastuzumab-based chemotherapy.